Disc Medicine reports positive Phase 2 data for bitopertin in EPP and updates for DISC-0974 and DISC-3405 at EHA 2024

Disc Medicine, Inc.

Bitopertin reduced protoporphyrin IX by 40% in 60 mg group and cut phototoxic reactions by 75.3% (p=0.011) in AURORA trial.
DISC-0974 showed 68.9% of non-transfusion dependent myelofibrosis patients had hemoglobin response ≥1.5 g/dL; one TD patient became transfusion independent.
DISC-3405 demonstrated >50% mean serum iron reduction sustained for at least 4 weeks at 300 mg dose in healthy volunteers.
No serious adverse events reported across all three programs to date.
Data were presented at European Hematology Association 2024 Congress on June 14, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.